Your browser doesn't support javascript.
loading
RNA interference screening methods to identify proliferation determinants and mechanisms of resistance to immune attack.
Zhang, Yong-Wei; Nasto, Rochelle E; Jablonski, Sandra A; Serebriiskii, Ilya G; Surana, Rishi; Murray, Joseph; Johnson, Michael; Riggins, Rebecca B; Clarke, Robert; Golemis, Erica A; Weiner, Louis M.
Afiliação
  • Zhang YW; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
  • Nasto RE; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, United States; School of Biomedical Engineering, Science and Health Systems, Drexel University, Philadelphia, PA, United States.
  • Jablonski SA; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
  • Serebriiskii IG; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, United States; Kazan Federal University, Kazan, Russia.
  • Surana R; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
  • Murray J; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
  • Johnson M; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
  • Riggins RB; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
  • Clarke R; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
  • Golemis EA; Program in Molecular Therapeutics, Fox Chase Cancer Center, Philadelphia, PA, United States.
  • Weiner LM; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States. Electronic address: weinerl@georgetown.edu.
Methods Enzymol ; 636: 299-322, 2020.
Article em En | MEDLINE | ID: mdl-32178823
ABSTRACT
We have used RNA interference (RNAi) screening technology to reveal unknown components of biological signaling pathways including survival mechanisms of estrogen-independent breast cancer cell growth and cancer cell resistance to immune attack. In this chapter, a detailed protocol describing the use of RNAi screening to identify factors important for the proliferation of estrogen-independent MCF7 breast cancer cells will be described. Resistance to therapies that target the estrogen pathway remains a challenge in the treatment of estrogen receptor-positive breast cancer. To address this challenge, small interfering-RNA (siRNA)-based libraries targeting an estrogen receptor (ER)- and aromatase-centered network, including 631 genes relevant to estrogen signaling, was designed and constructed for RNAi screening. This protocol will include the following parts (1) selection of RNAi transfection reagent for specific cells; (2) optimization of RNAi screening conditions using Z'-factor; (3) procedure of ER-network gene siRNA library screening using automated machines under optimized experimental conditions; and (4) method of analysis for RNAi screening data to identify specific determinants important for cell proliferation. 46 genes were found to be selectively required for the survival of estrogen-independent MCF7-derived cells.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptores de Estrogênio Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies / Screening_studies Limite: Female / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article